BioWorld

June 1, 2009

Celldex Extending Pipeline, Cash Runway in $95M CuraGen Deal

Celldex Therapeutics Inc. took another step toward expanding its pipeline, agreeing to buy CuraGen Corp. in a $94.5 million stock deal that will bring in 11 drug candidates and some added cash. (BioWorld Today) Read More

ASCO 2009 Kicks Off with Data in Hematologic Malignancies

Catalyst's Phase II Cocaine-Habit Failure Puts Squeeze on Finances

FDA Says Restrictive REMS Plan for Opioid Products Not Imminent

FDA Panel Backs Genmab's Arzerra in Refractory CLL

Other News To Note

Appointments And Advancements

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026